Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

被引：0

作者：

Gee-Chen Chang

David Chi-Leung Lam

Chun-Ming Tsai

Yuh-Min Chen

Jin-Yuan Shih

Shyam Aggarwal

Shuhang Wang

Sang-We Kim

Young-Chul Kim

Ibrahim Wahid

Rubi Li

Darren Wan-Teck Lim

Virote Sriuranpong

Raymond Tsz-Tong Chan

Robert M. Lorence

Philippe Carriere

Christina Raabe

Agnieszka Cseh

Keunchil Park

机构：

[1] Taichung Veterans General Hospital,Division of Chest Medicine, Department of Internal Medicine

[2] Chung Shan Medical University Hospital,Division of Pulmonary Medicine, Department of Internal Medicine

[3] Chung Shan Medical University,Institute of Medicine and School of Medicine

[4] Queen Mary Hospital,Department of Chest Medicine

[5] The University of Hong Kong,Asan Medical Center

[6] Taipei Veterans General Hospital,Samsung Medical Center

[7] Taipei Veterans General Hospital,undefined

[8] and School of Medicine,undefined

[9] National Yang-Ming Medical University,undefined

[10] National Taiwan University Hospital,undefined

[11] Sir Ganga Ram Hospital Rajinder Nagar,undefined

[12] Beijing Cancer Hospital,undefined

[13] University of Ulsan College of Medicine,undefined

[14] Chonnam National University,undefined

[15] Hwasun Hospital,undefined

[16] Beacon International Specialist Centre,undefined

[17] St Luke’s Medical Center,undefined

[18] National Cancer Centre,undefined

[19] Chulalongkorn University and the King Chulalongkorn Memorial Hospital,undefined

[20] Hong Kong Pacific Centre,undefined

[21] Boehringer Ingelheim Pharmaceuticals,undefined

[22] Inc.,undefined

[23] Boehringer Ingelheim International GmbH,undefined

[24] Boehringer Ingelheim RCV GmBH & Co. KG,undefined

[25] Sungkyunkwan University School of Medicine,undefined

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Afatinib; mutations; Lung cancer; Named patient use; NSCLC; Uncommon ; mutations;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：841 / 850

页数：9

共 50 条

[21] A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations [J].

Hisashi Tanaka ;

Kageaki Taima ;

Yoshihito Tanaka ;

Masamichi Itoga ;

Yoshiko Ishioka ;

Hideyuki Nakagawa ;

Keisuke Baba ;

Yukihiro Hasegawa ;

Shingo Takanashi ;

Sadatomo Tasaka .

Medical Oncology, 2018, 35

[22] A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations [J].

Tanaka, Hisashi ;

Taima, Kageaki ;

Tanaka, Yoshihito ;

Itoga, Masamichi ;

Ishioka, Yoshiko ;

Nakagawa, Hideyuki ;

Baba, Keisuke ;

Hasegawa, Yukihiro ;

Takanashi, Shingo ;

Tasaka, Sadatomo .

MEDICAL ONCOLOGY, 2018, 35 (03)

[23] An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations [J].

Park, Keunchil ;

Kim, Jin-Soo ;

Kim, Joo-Hang ;

Kim, Young-Chul ;

Kim, Hoon-Gu ;

Cho, Eun Kyung ;

Jin, Jong-Youl ;

Kim, Miyoung ;

Marten, Angela ;

Kang, Jin-Hyoung .

BMC CANCER, 2021, 21 (01)

[24] Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer [J].

Normanno, Nicola ;

Denis, Marc G. ;

Thress, Kenneth S. ;

Ratcliffe, Marianne ;

Reck, Martin .

ONCOTARGET, 2017, 8 (07) :12501-12516

[25] Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study [J].

Kanazu, Masaki ;

Mori, Masahide ;

Kimura, Madoka ;

Nishino, Kazumi ;

Shiroyama, Takayuki ;

Nagatomo, Izumi ;

Ihara, Shoichi ;

Komuta, Kiyoshi ;

Suzuki, Hidekazu ;

Hirashima, Tomonori ;

Kumagai, Toru ;

Imamura, Fumio .

THORACIC CANCER, 2021, 12 (01) :90-96

[26] Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial [J].

Wu, Yi-Long ;

Xu, Chong-Rui ;

Hu, Cheng-Ping ;

Feng, Jifeng ;

Lu, Shun ;

Huang, Yunchao ;

Li, Wei ;

Hou, Mei ;

Shi, Jian Hua ;

Maerten, Angela ;

Fan, Jean ;

Peil, Barbara ;

Zhou, Caicun .

ONCOTARGETS AND THERAPY, 2018, 11 :8575-8587

[27] A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404 [J].

Ninomiya, Takashi ;

Nogami, Naoyuki ;

Kozuki, Toshiyuki ;

Harada, Daijiro ;

Kubo, Toshio ;

Ohashi, Kadoaki ;

Kuyama, Shoichi ;

Kudo, Kenichiro ;

Bessho, Akihiro ;

Fukamatsu, Nobuaki ;

Fujimoto, Nobukazu ;

Aoe, Keisuke ;

Shibayama, Takuo ;

Sugimoto, Keisuke ;

Takigawa, Nagio ;

Hotta, Katsuyuki ;

Kiura, Katsuyuki .

LUNG CANCER, 2018, 115 :103-108

[28] Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations [J].

Ko, Ryo ;

Shukuya, Takehito ;

Imamura, Chiyo K. ;

Tokito, Takaaki ;

Shimada, Naoko ;

Koyama, Ryo ;

Yamada, Kazuhiko ;

Ishii, Hidenobu ;

Azuma, Koichi ;

Takahashi, Kazuhisa .

TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) :183-+

[29] An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations [J].

Keunchil Park ;

Jin-Soo Kim ;

Joo-Hang Kim ;

Young-Chul Kim ;

Hoon-Gu Kim ;

Eun Kyung Cho ;

Jong-Youl Jin ;

Miyoung Kim ;

Angela Märten ;

Jin-Hyoung Kang .

BMC Cancer, 21

[30] Intracranial Efficacy of Afatinib as First-line Treatment in Common/Uncommon EGFR-Mutant Advanced Non-small Cell Lung Cancer Patients [J].

Liang, Y. ;

Kang, L. ;

Lin, Y. ;

Mai, J. ;

Zou, Q. ;

Huang, C. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S345-S346

← 1 2 3 4 5 →